John Estess, MD
Cardiovascular Disease · Tupelo, MSNPI 1497865638
Payments from drug & device makers
Across 238 payments — averaging $1746.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$285K
- CSL Behring$127K
- AstraZeneca$577
- Merck$461
- Boehringer Ingelheim$276
- Abiomed$267
- plus $2K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 17 | $285,482 |
| CSL Behring | 89 | $126,671 |
| AstraZeneca | 22 | $577 |
| Merck | 26 | $461 |
| Boehringer Ingelheim | 5 | $276 |
| Abiomed | 8 | $267 |
| Novartis | 13 | $191 |
| Thrombolex, Inc. | 1 | $186 |
| Nuwellis, Inc. | 2 | $176 |
| Boston Scientific | 3 | $161 |
| Johnson & Johnson | 11 | $141 |
| Novo Nordisk | 3 | $134 |
| Bard Peripheral Vascular, Inc. | 1 | $134 |
| Alnylam Pharmaceuticals Inc. | 5 | $95 |
| Cook Medical LLC | 1 | $92 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $87 |
| Medtronic | 1 | $84 |
| Biotronik Inc. | 1 | $80 |
| Sanofi-aventis U.S. LLC | 5 | $66 |
| E.r. Squibb & Sons, L.L.C. | 4 | $56 |
| Daxor Corporation | 1 | $50 |
| Lexicon Pharmaceuticals, Inc. | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Akcea Therapeutics, Inc. | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Bracco Diagnostics Inc. | 1 | $13 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
How this compares
$415,685 in reported general payments places this provider in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Tupelo
- Barry BertoletTupelo$6.4M
- Benjamin BlossomTupelo$91K
- Michael BolerTupelo$6K
- Dharmesh PatelSouthaven$1.9M
- James HaysJackson$782K
- Donny StokesJackson$277K
- Mahmoud ZayedPascagoula$103K
- James HaysJackson$65K
- James BenslerJackson$64K
- Michael HallJackson$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.